Kodiak Sciences (KOD) closed at $111.19 on November 13, 2026, up 2.7% from the previous close, on volume of 884,260 shares (30-day average 1,147,228).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 16, 2026 | Calendar Call Spread | 16-Oct-26 : 15-Jan-27 55 C | 6,408 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Kodiak Sciences GAAP EPS of -$1.05 beats by $0.01
Seeking Alpha News (Thu, 12-Nov 4:37 PM ET)
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2026 Financial Results
PRNewswire (Thu, 12-Nov 4:00 PM ET)
Kodiak Sciences to Present at Three Upcoming Investor Conferences
PRNewswire (Wed, 11-Nov 6:44 PM ET)
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026
PRNewswire (Wed, 7-Oct 7:00 AM ET)
4 Explosive Stories Enter the Investor Spotlight
Globe Newswire (Mon, 28-Sep 11:51 AM ET)
Market Chameleon (Mon, 28-Sep 5:52 AM ET)
Kodiak Sciences Sets Sept. 28 Webcast for DAYBREAK Phase 3 Topline Results in Wet AMD
Market Chameleon (Mon, 28-Sep 3:06 AM ET)
PRNewswire (Fri, 25-Sep 6:02 PM ET)
Market Chameleon (Wed, 1-Apr 5:47 AM ET)
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Kodiak Sciences trades on the NASDAQ stock market under the symbol KOD.
As of November 13, 2026, KOD stock price climbed to $111.19 with 884,260 million shares trading.
KOD has a beta of 1.02, meaning it tends to be more sensitive to market movements. KOD has a correlation of 0.01 to the broad based SPY ETF.
KOD has a market cap of $6.99 billion. This is considered a Mid Cap stock.
In the last 3 years, KOD traded as high as $112.79 and as low as $1.75.
The top ETF exchange traded funds that KOD belongs to (by Net Assets): XBI, VTI, IWM, IBB, VXF.
KOD has outperformed the market in the last year with a price return of +489.2% while the SPY ETF gained +13.4%. KOD has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +178.1% and +12.1%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
KOD support price is $103.61 and resistance is $112.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KOD shares will trade within this expected range on the day.
